ZM-2311 / Simcere - LARVOL DELTA

ZM-2311 a novel and highly potent Polθ inhibitor demonstrates synergistically anti-tumor activities in combination with different therapeutics (AACR 2024) - "These results indicate a potential application expansion of ZM-2311 to HR-proficient tumors, which is expected to bring better efficacy and reduced hematotoxicity. Taken together, ZM-2311 has proved to be a highly potent Polθ inhibitor and has promising combination potential with multiple therapy strategies."

Combination therapy • Oncology • BRCA1 • BRCA2 • POLQ • SHLD2 • TP53BP1